Nutrition in Chronic Liver Disease and Cirrhosis

Key Nutritional Targets for Patients with Cirrhosis

If you have liver cirrhosis, what you eat matters as much as any medication. Malnutrition is a recognised complication of cirrhosis that develops silently - often in patients who look well-fed - because the diseased liver alters how the body stores and uses nutrients. These EASL Clinical Practice Guidelines pull together the full evidence base on nutrition in chronic liver disease, from the right protein targets to what happens to your bones and muscles, and what to eat before and after a liver transplant.

The panel reviewed literature across multiple databases and used the GRADE system to classify the strength and quality of each recommendation. The result is a comprehensive guide that liver specialists, dietitians, and informed patients can use to understand what nutrition decisions the evidence actually supports.

Nutritional Screening and Assessment

EASL recommends that every patient with cirrhosis undergo a rapid nutritional screen. Two factors automatically classify a patient as high risk: a body mass index (BMI) below 18.5 kg/m², or a Child-Pugh C classification. ref 7 For all other patients, validated screening tools should be used. The Royal Free Hospital Nutritional Prioritizing Tool (RFH-NPT) takes under 3 minutes, can be used by non-specialist staff, and correlates with disease severity and clinical deterioration. ref 8

Once a patient is identified as at risk, a detailed nutritional assessment by a registered dietitian is recommended. In the outpatient setting, each component of nutritional status should be reassessed every 1 to 6 months. For patients in hospital, assessment should occur at admission and periodically throughout the stay. ref 9 The RFH-GA (global assessment version) stratifies patients into three categories - adequately nourished, moderately malnourished, or severely malnourished - based on dry-weight BMI and mid-arm muscle circumference (MAMC). ref 71

Measuring Muscle Mass: Tools and Cutoffs

Sarcopenia assessment is a core part of the nutritional evaluation. The gold standard is CT scan analysis at the L3 vertebral level, which measures the cross-sectional area of abdominal skeletal muscles and normalises it to height. ref 10 Cutoff values for defining sarcopenia in liver transplant candidates are 50 cm²/m² for men and 39 cm²/m² for women. ref 11

A meta-analysis confirmed that CT-defined sarcopenia is independently associated with post-transplant mortality, with a pooled hazard ratio of 1.84 (95% CI: 1.11 to 3.05), independent of MELD score. ref 12 Where CT is not available, mid-arm muscle circumference (MAMC) is a practical bedside alternative, with an accuracy (AUROC) of 0.75 in men and 0.84 in women compared to CT. ref 13 Handgrip strength is another simple, inexpensive option that predicts both complications and mortality in cirrhotic patients. ref 14

Assessing Frailty

Frailty refers to reduced physiologic reserve and is closely linked to malnutrition in cirrhosis. The Fried frailty phenotype (measuring unintentional weight loss, exhaustion, grip strength, walking speed, and physical activity) independently predicts liver transplant waitlist mortality, even after adjusting for MELD score. ref 15 The Short Physical Performance Battery (SPPB), which takes 2-3 minutes, also predicts waitlist mortality. ref 16

Energy and Protein Requirements in Cirrhosis

Cirrhosis creates a state of accelerated starvation. Even after a short fast, the cirrhotic body switches from burning glucose to burning fat and then muscle protein, at a rate far faster than in healthy individuals. Total daily energy needs typically range from 28 to 37.5 kcal/kg of body weight per day in cirrhosis. ref 19

EASL recommends a minimum energy intake of 35 kcal/kg of actual body weight per day. When fluid retention is present (ascites), body weight should be corrected to dry weight before calculating the target: subtract approximately 5% for mild ascites, 10% for moderate, and 15% for severe ascites, with an additional 5% subtracted if bilateral pedal oedema is present. ref 20

For protein, the recommendation is 1.2 to 1.5 g per kg of actual body weight per day to prevent and reverse sarcopenia. ref 21 This is above what many patients have been told in the past. Research confirms cirrhotic patients can utilise up to 1.8 g/kg/day. ref 22 A multidisciplinary nutrition team approach to hitting these targets improved both survival rates and quality of life in cirrhotic patients in a retrospective study. ref 25

The Late Evening Snack: Why it Matters

One of the most practical and evidence-based recommendations in these guidelines is the late evening snack. Because the gap between the last meal of the day and breakfast is the longest fasting period, it triggers the most muscle catabolism in cirrhotic patients. Eating a small protein-containing snack before bed - combined with a protein-containing breakfast - shortens this overnight fasting window and was shown to improve metabolic outcomes and quality of life. ref 24 EASL recommends aiming for 3 main meals and 3 snacks per day to spread caloric and protein intake as evenly as possible throughout the day.

Sarcopenia and Muscle Loss

Sarcopenia - the progressive loss of skeletal muscle mass and function - is now recognised as an independent complication of cirrhosis, not just a marker of overall disease severity. It is linked to infections, hepatic encephalopathy, fluid retention (ascites), and lower survival. ref 4 ref 5 Several interacting mechanisms drive muscle loss in cirrhosis, including elevated ammonia levels in muscle tissue, reduced testosterone and growth hormone, increased muscle protein breakdown, and impaired protein synthesis.

Nutrition and physical activity are the two main strategies patients can act on. Meeting the protein target of 1.2-1.5 g/kg/day ref 21 and the energy target of 35 kcal/kg/day ref 20 is the nutritional foundation. On top of that, BCAA supplementation has been shown to improve survival specifically in sarcopenic patients awaiting liver transplantation, though this benefit was not observed in non-sarcopenic patients. ref 63

Exercise Recommendations for Cirrhosis

Physical activity is a potent stimulus for muscle maintenance. Aerobic (endurance) exercise improves overall exercise tolerance and functional capacity but does not reliably increase muscle mass on its own. ref 26 Resistance exercise directly promotes skeletal muscle mass gain. ref 27 EASL therefore recommends a combination of both types, confirming that a moderate-intensity exercise regimen is beneficial in cirrhosis. ref 29

One important note: exercise transiently increases muscle ammonia generation and portal pressure in cirrhotic patients. ref 28 This means exercise intensity and type must be tailored to the individual. Patients with significant portal hypertension or varices should discuss exercise plans with their hepatologist before starting. Beginning at moderate intensity and progressing gradually is the recommended approach.

Obesity in Cirrhosis

The rise of MASH as a leading cause of cirrhosis means obesity is increasingly common in the cirrhosis population. It is now found in 20-35% of patients with compensated cirrhosis, regardless of the original cause of their liver disease. ref 30 Obesity significantly accelerates liver disease progression. In the HALT-C trial, the risk of histological worsening or clinical decompensation increased by 14% for each BMI quartile increase, and by 35% in patients whose body weight increased by more than 5% in one year. ref 31

For obese patients with compensated cirrhosis, the recommended weight loss goal is 5-10% of body weight. ref 32 This is best achieved through a moderately hypocaloric diet of 500-800 kcal/day below maintenance needs, combined with supervised physical activity. Protein intake during weight loss must be maintained above 1.5 g/kg of ideal body weight per day to avoid losing muscle instead of fat. ref 33

Important: BMI alone can be misleading in cirrhosis. Fluid retention from ascites artificially inflates body weight. The dry weight (body weight corrected for estimated ascites volume) should always be used when calculating BMI thresholds. ref 18

Vitamins and Micronutrients

The liver plays a central role in processing and storing vitamins, which means liver disease often leads to widespread nutritional deficiencies. A review of patients evaluated for liver transplantation found that the majority had both vitamin A and vitamin D deficiency. ref 35

Vitamin D

Vitamin D deficiency - defined as a blood level below 20 ng/ml - is the most common nutritional deficiency in chronic liver disease, affecting 64-92% of patients. ref 36 The rate is highest in cholestatic conditions and in patients with more advanced disease. EASL recommends checking vitamin D (25-hydroxyvitamin D) levels in all cirrhotic patients and supplementing with oral vitamin D when levels fall below 20 ng/ml, targeting a serum level above 30 ng/ml. ref 37 The supplementation dose is typically 400-800 IU per day orally, or 260 micrograms every two weeks.

Vitamin K and Thiamine

Vitamin K deficiency is common in patients with jaundice or cholestatic liver disease and may require parenteral (injectable) supplementation in severe cases. ref 38 Thiamine (vitamin B1) deficiency occurs in patients with both alcohol-related and non-alcohol-related cirrhosis. Evidence of Wernicke's encephalopathy - a serious brain complication of thiamine deficiency - is often found in patients who showed no clinical signs during their lifetime. ref 39 If Wernicke's encephalopathy is suspected in an acutely unwell patient with liver disease, urgent parenteral thiamine replacement is mandatory before giving any glucose-containing fluids.

Sodium Restriction in Ascites

For patients with fluid in the abdomen (ascites), a modest sodium restriction is appropriate. EASL recommends a target of 80 mmol per day, which equals 2 grams of sodium or approximately 5 grams of table salt. Crucially, sodium should not be restricted below 60 mmol per day, because overly restrictive diets become so unpalatable that patients eat less overall, worsening their nutritional status. ref 40

Nutrition in Hepatic Encephalopathy

Hepatic encephalopathy (HE) - episodes of confusion or altered consciousness triggered by elevated ammonia - occurs far more often in malnourished patients. There is a clear inverse relationship: the less skeletal muscle mass you have, the higher your blood ammonia tends to be. ref 41 This is because muscle tissue is one of the body's main ammonia-clearing organs, using the enzyme glutamine synthetase to convert ammonia into the harmless molecule glutamine. ref 43 Sarcopenia (assessed by skeletal muscle index) is an independent risk factor for developing HE after TIPS shunt placement. ref 42

Protein Sources and BCAA Supplements in HE

For patients who find meat protein difficult to tolerate, switching to dairy or vegetable protein sources may be better tolerated and produce less ammonia. ref 45 Branched-chain amino acid (BCAA) supplements provide a practical way for patients who struggle with meat protein to still reach their total nitrogen targets.

The strongest evidence for BCAA in HE comes from a Cochrane meta-analysis covering 16 randomised controlled trials and 827 patients. Oral BCAA supplementation had a positive impact on HE symptoms. However, the same review found no significant effect on mortality, quality of life, or overall nutritional status from BCAA alone. ref 46

One randomised trial found that a structured nutritional intervention - 30-35 kcal/kg/day plus 1.0-1.5 g/kg/day of vegetable protein for 6 months - improved neuropsychiatric performance and reduced the risk of progressing from minimal to overt HE. ref 47 This underlines that meeting overall calorie and protein targets is more important than any specific supplement.

In patients with grade III-IV HE who cannot eat safely, nutrition should be provided by nasogastric tube. For critically ill cirrhotic patients with HE, BCAA-enriched solutions should be used to help resolve the episode. ref 69

Bone Disease in Cirrhosis (Hepatic Osteodystrophy)

Liver disease leads to a spectrum of bone disorders collectively called hepatic osteodystrophy, most often osteoporosis. Approximately 30% of patients with chronic liver disease develop osteoporosis. ref 48 Rates are even higher in cholestatic conditions such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). ref 49 Among patients being evaluated for liver transplantation, about 30% have osteoporosis. ref 50 Fracture rates range from 7-35% - with the highest risk in postmenopausal women and patients taking long-term corticosteroids. ref 51

Bone Density Screening and the DEXA Schedule

EASL recommends DEXA bone density measurement in all patients with cirrhosis, particularly those with cholestatic disease, those on long-term corticosteroids, and anyone being evaluated for transplantation. Bone density is classified using T-scores from the WHO: a T-score at or below -2.5 is osteoporosis; a score between -1 and -2.5 is osteopenia. ref 52 A T-score below -1.5 signals a high risk of hip and vertebral fractures and is a practical threshold for starting specific bone-protective therapy. ref 53

Transplantation carries a significant bone risk: 25-35% of patients experience fractures within the first year after surgery. ref 54 Improvements in post-transplant bone management have reduced this rate in recent years. Bisphosphonates are recommended both for patients with established osteoporosis and for those on the transplant waiting list. ref 56 Transdermal oestrogen therapy can prevent bone loss in women with PBC and in postmenopausal women after liver transplantation, without adverse effects on the liver. ref 57

Nutrition Around Liver Transplantation

Nutritional status is one of the most important determinants of transplant success. Both extremes carry significant risk: a BMI below 18.5 (severe undernutrition) and a BMI above 40 (severe obesity) are both independently associated with increased mortality and morbidity after liver transplantation. ref 58 Sarcopenia and frailty on the waiting list increase risk of complications and death both before and after surgery. ref 59 Critically, a protein intake below 0.8 g/kg/day while waiting for transplant is associated with higher waitlist mortality. ref 60

Pre-Transplant Nutritional Targets

Standard nutrition formulas are preferred over specialised regimens such as BCAA-enriched or immune-enhancing formulas, which have not been shown to improve morbidity or mortality in transplant surgical trials. ref 62 One important exception: BCAA supplementation improved survival in sarcopenic patients on the transplant waiting list, but this benefit was not seen in non-sarcopenic patients. ref 63

Post-Transplant Nutrition and Recovery

After transplant surgery, nutrition should begin as early as possible. EASL recommends starting enteral (tube) feeding preferably within 12-24 hours of the operation, as this reduces infection rates and other bacterial complications compared with waiting. ref 64

Once past the immediate post-operative phase, the nutritional targets increase to match recovery needs: 35 kcal/kg body weight per day and 1.5 g protein/kg body weight per day. ref 65 For obese transplant recipients, targets are calculated from ideal body weight: 25 kcal/kg ideal BW/day and 2.0 g protein/kg ideal BW/day. ref 66

For critically ill cirrhotic patients in intensive care, energy targets rise to 35-40 kcal/kg body weight per day (or 1.3 times the measured resting energy expenditure) ref 67, with protein at 1.2-1.3 g/kg/day. ref 68 In cirrhotic patients with alcoholic hepatitis, a caloric intake below 21.5 kcal/kg/day has been independently associated with higher mortality. ref 70

Related on LiverDecoded

Frequently Asked Questions